UCB's Keppra gets key approval to treat newly diagnosed epilepsy patients

By Elaine Rigoli

Tampa, Fla., Aug. 18 - UCB said it has received approval of Keppra (levetiracetam) by the European Commission as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.

The monotherapy approval reflects the company's research that supports the expanding role of Keppra in epilepsy management, officials noted.

UCB is a global biopharmaceutical company located in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.